Real-world application of physiologically based pharmacokinetic models in drug discovery.

IF 4.4 3区 医学 Q1 PHARMACOLOGY & PHARMACY
Drug Metabolism and Disposition Pub Date : 2025-01-01 Epub Date: 2024-11-22 DOI:10.1124/dmd.122.001036
Laura G A Santos, Swati Jaiswal, Kuan-Fu Chen, Hannah M Jones, Ian E Templeton
{"title":"Real-world application of physiologically based pharmacokinetic models in drug discovery.","authors":"Laura G A Santos, Swati Jaiswal, Kuan-Fu Chen, Hannah M Jones, Ian E Templeton","doi":"10.1124/dmd.122.001036","DOIUrl":null,"url":null,"abstract":"<p><p>The utility of physiologically based pharmacokinetic (PBPK) models in support of drug development has been well documented. During the discovery stage, PBPK modeling has increasingly been applied for early risk assessment, prediction of human dose, toxicokinetic dose projection, and early formulation assessment. Previous review articles have proposed model-building and application strategies for PBPK-based first-in-human predictions with comprehensive descriptions of the individual components of PBPK models. This includes the generation of decision trees based on literature reviews to guide the application of PBPK models in the discovery setting. The goal of this minireview is to provide additional guidance on the real-world application of PBPK models in support of the discovery stage of drug development, to assist in decision making. We have illustrated our recommended approach through description of case examples where PBPK models have been successfully applied to aid in human pharmacokinetic projection, candidate selection, and prediction of drug interaction liability for parent and metabolite. Through these case studies, we have highlighted fundamental issues, including preverification in preclinical species, the application of empirical scalars in the prediction of in vivo clearance from in vitro systems, in silico prediction of permeability, and the exploration of aqueous and biorelevant solubility data to predict dissolution. In addition, current knowledge gaps have been highlighted and future directions proposed. SIGNIFICANCE STATEMENT: Through description of 3 case studies, this minireview highlights the fundamental principles of physiologically based pharmacokinetic application during drug discovery. These include preverification of the model in preclinical species, application of empirical scalars where necessary in the prediction of clearance, in silico prediction of permeability, and the exploration of aqueous and biorelevant solubility data to predict dissolution. In addition, current knowledge gaps have been highlighted and future directions proposed.</p>","PeriodicalId":11309,"journal":{"name":"Drug Metabolism and Disposition","volume":"53 1","pages":"100015"},"PeriodicalIF":4.4000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Metabolism and Disposition","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1124/dmd.122.001036","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/22 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

The utility of physiologically based pharmacokinetic (PBPK) models in support of drug development has been well documented. During the discovery stage, PBPK modeling has increasingly been applied for early risk assessment, prediction of human dose, toxicokinetic dose projection, and early formulation assessment. Previous review articles have proposed model-building and application strategies for PBPK-based first-in-human predictions with comprehensive descriptions of the individual components of PBPK models. This includes the generation of decision trees based on literature reviews to guide the application of PBPK models in the discovery setting. The goal of this minireview is to provide additional guidance on the real-world application of PBPK models in support of the discovery stage of drug development, to assist in decision making. We have illustrated our recommended approach through description of case examples where PBPK models have been successfully applied to aid in human pharmacokinetic projection, candidate selection, and prediction of drug interaction liability for parent and metabolite. Through these case studies, we have highlighted fundamental issues, including preverification in preclinical species, the application of empirical scalars in the prediction of in vivo clearance from in vitro systems, in silico prediction of permeability, and the exploration of aqueous and biorelevant solubility data to predict dissolution. In addition, current knowledge gaps have been highlighted and future directions proposed. SIGNIFICANCE STATEMENT: Through description of 3 case studies, this minireview highlights the fundamental principles of physiologically based pharmacokinetic application during drug discovery. These include preverification of the model in preclinical species, application of empirical scalars where necessary in the prediction of clearance, in silico prediction of permeability, and the exploration of aqueous and biorelevant solubility data to predict dissolution. In addition, current knowledge gaps have been highlighted and future directions proposed.

基于生理的药代动力学模型在药物发现中的实际应用。
基于生理的药代动力学(PBPK)模型在支持药物开发中的应用已经得到了很好的证明。在发现阶段,PBPK模型越来越多地应用于早期风险评估、人体剂量预测、毒性动力学剂量预测和早期配方评估。先前的综述文章提出了基于PBPK的首次人体预测的模型构建和应用策略,并对PBPK模型的各个组成部分进行了全面描述。这包括基于文献综述的决策树的生成,以指导PBPK模型在发现设置中的应用。这篇迷你综述的目的是为PBPK模型的实际应用提供额外的指导,以支持药物开发的发现阶段,协助决策。我们通过描述PBPK模型成功应用于人类药代动力学预测、候选药物选择以及母体和代谢物药物相互作用预测的案例示例说明了我们推荐的方法。通过这些案例研究,我们强调了基本问题,包括临床前物种的预验证,经验标量在体外系统体内清除率预测中的应用,渗透率的计算机预测,以及水溶性和生物相关溶解度数据的探索,以预测溶解。此外,还强调了当前的知识差距,并提出了未来的方向。意义声明:通过对3个案例研究的描述,本综述强调了药物发现过程中基于生理的药代动力学应用的基本原则。这些包括在临床前物种中对模型进行预验证,在预测清除时必要时应用经验标量,在计算机上预测渗透性,以及探索水和生物相关的溶解度数据以预测溶解。此外,还强调了当前的知识差距,并提出了未来的方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.50
自引率
12.80%
发文量
128
审稿时长
3 months
期刊介绍: An important reference for all pharmacology and toxicology departments, DMD is also a valuable resource for medicinal chemists involved in drug design and biochemists with an interest in drug metabolism, expression of drug metabolizing enzymes, and regulation of drug metabolizing enzyme gene expression. Articles provide experimental results from in vitro and in vivo systems that bring you significant and original information on metabolism and disposition of endogenous and exogenous compounds, including pharmacologic agents and environmental chemicals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信